MS4A1 and myeloid sarcoma: In people with MS and comorbid RA, teriflunomide and its precursor leflunomide, as well as anti-CD20 therapies, are either approved by the EMA and FDA for their respective indications or have demonstrated beneficial treatment effects in phase III studies, making them the treatments of choice [8–19].